Healthcare 2013, 1(1), 96-99; doi:10.3390/healthcare1010096
Scalp In-Transit Metastatic Melanoma Treated with Interleukin-2 and Pulsed Dye Laser
Department of Dermatology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
*
Author to whom correspondence should be addressed.
Received: 20 August 2013 / Revised: 16 October 2013 / Accepted: 21 October 2013 / Published: 25 October 2013
Abstract
No particular regimen is considered standard therapy for widespread metastatic melanoma, although surgery is the primary choice for regional nodal metastases. Systemic interleukin-2 (IL-2) is an effective immunotherapy for melanoma, but standard doses are associated with severe toxicity. We report a patient who was treated with intralesional low-dose IL-2 and V-beam pulsed dye laser for the treatment of scalp melanoma metastases. This treatment resulted in rapid regression of metastatic tumors with limited adverse effects. View Full-TextKeywords:
interleukin-2; melanoma; pulsed dye laser therapy
▼
Figures
Figure 1
This is an open access article distributed under the Creative Commons Attribution License (CC BY 3.0).
Share & Cite This Article
MDPI and ACS Style
Wang, M.Z.; Brewer, J.D. Scalp In-Transit Metastatic Melanoma Treated with Interleukin-2 and Pulsed Dye Laser. Healthcare 2013, 1, 96-99.
Related Articles
Article Metrics
Comments
[Return to top]
Healthcare
EISSN 2227-9032
Published by MDPI AG, Basel, Switzerland
RSS
E-Mail Table of Contents Alert